Evaluating Ruxolitinib in Steroid Refractory Chronic GvHD

Dr. Zeiser discusses the dynamic clinical evolution of Graft vs Host Disease (GvHD) in a concise overview, gaining insights into its progression and changing manifestations over time.

Two experts explore the essentials of Graft vs Host Disease (GvHD), understanding its symptoms, diagnosis, and distinguishing characteristics between acute and chronic forms.

Explore the primary treatment options for chronic Graft vs Host Disease (cGvHD) and delve into the challenges associated with prolonged steroid use, focusing on dosing strategies and adverse event management.

Dr. Zeiser discusses the recent data presented at ASH 2023 of the REACH3 trial.

Experts discuss the treatments for steroid-refractory/dependent chronic Graft vs Host Disease (SR/D cGvHD), focusing on the unique mechanisms and applications of belumosudil and role of ibrutinib.

Dr. Zeiser and Dr. Chao review ongoing clinical trials in the management of cGvHD – specifically the use of axatilimab and abatacept in SR/D cGvHD.

Dr Chao provides his insights into the ongoing complexities that clinicians face and shaping a comprehensive understanding of the areas requiring further attention and innovation in cGvHD management.